Mayne said Thursday that it will distribute the product, a generic version of Bupap tablets (butalbital acetaminophen 50 mg/300 mg) from Valeant Pharmaceuticals International, on behalf of its partner Mikart Inc., the developer and manufacturer of the generic medicine.
“We are very pleased to have licensed this product from Mikart Inc., one of our strategic partners,” stated Scott Richards, chief executive officer of Mayne Pharma. “This will be the first generic alternative to Bupap and will bring patients and payers improved medication affordability.”
Butalbital, a barbiturate, relaxes muscle contractions in a tension headache, while acetaminophen provides added pain relief.
U.S. sales for the branded product totaled approximately $27 million for the 12 months ended Dec. 31, 2016, according to IMS Health data reported by Mayne Pharma.